title: Epigenetic regulation of PRAME in acute myeloid leukemia is different compared to CD34+ cells from healthy donors: effect of 5-AZA treatment.
abstract: PRAME is a tumor associated antigen (TAA) of particular interest since it is widely expressed by lymphoid and myeloid malignancies. Several studies have associated high PRAME RNA levels with good prognosis in acute myeloid leukemia (AML). PRAME expression is regulated at the epigenetic level. For this reason inhibitors of DNA methylation, such as 5-azacytidine, can modulate the expression of this TAAs. In the current study we analyzed the effect of 5-azaC on the expression of PRAME in blasts versus CD34+ cells from healthy donors in an attempt to increase its expression, thus inducing a potential target for therapeutic strategies.
authors.affiliation: Hematology Unit, Hospital Universitario de Salamanca, Salamanca, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Gutierrez-Cosío
authors.forename: L
authors.initials: L
authors.lastname: de la Rica
authors.forename: E
authors.initials: E
authors.lastname: Ballestar
authors.forename: C
authors.initials: C
authors.lastname: Santamaría
authors.forename: L I
authors.initials: LI
authors.lastname: Sánchez-Abarca
authors.forename: T
authors.initials: T
authors.lastname: Caballero-Velazquez
authors.forename: B
authors.initials: B
authors.lastname: Blanco
authors.forename: C
authors.initials: C
authors.lastname: Calderón
authors.forename: C
authors.initials: C
authors.lastname: Herrero-Sánchez
authors.forename: S
authors.initials: S
authors.lastname: Carrancio
authors.forename: L
authors.initials: L
authors.lastname: Ciudad
authors.forename: C
authors.initials: C
authors.lastname: Cañizo
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: J A
authors.initials: JA
authors.lastname: Pérez-Simón
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000378:metabolism; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D001374:Azacitidine / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001782:Blood Donors; D001854:Bone Marrow Cells / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D018899:CpG Islands / Q000235:genetics; D020732:Cytogenetic Analysis; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000502:physiology; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006262:Health; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D013234:Stem Cells / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology
chemical_list: D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; C404944:PRAME protein, human; D001374:Azacitidine